Table 3

Estimated ranking of interventions according to different outcomes

InterventionsMedian rank (95% CrI)Pbest (%)SUCRA (%)
HA RRMS
ARR at 24 months
 Fingolimod 0.5 mg once daily1 (1, 2)64.082.0
 DMF 240 mg two times a day2 (1, 2)36.067.9
 Placebo3 (3, 3)0.00.1
3-month disability progression at 24 months
 Natalizumab 300 mg1 (1, 2)79.289.0
 Fingolimod 0.5 mg once daily2 (1, 3)20.446.1
 Placebo3 (2, 3)0.414.9
RES RRMS
ARR at 24 months
 Natalizumab 300 mg1 (1, 2)93.196.5
 Fingolimod 0.5 mg once daily2 (1, 2)6.953.4
 Placebo3 (3, 3)0.00.1
3-month disability progression at 24 months
 Natalizumab 300 mg1 (1, 2)79.289.0
 Fingolimod 0.5 mg once daily2 (1, 3)20.446.1
 Placebo3 (2, 3)0.414.9
6-month disability progression at 24 months
 Natalizumab 300 mg1 (1, 2)81.990.8
 Fingolimod 0.5 mg once daily2 (1, 3)49.447.0
 Placebo3 (3, 3)0.112.2
  • ARR, annualised relapse rate; CrI, credible interval; DMF, dimethyl fumarate; HA, highly active; RES, rapidly evolving severe; RRMS, relapsing–remitting multiple sclerosis; SUCRA, surface under the cumulative ranking curve.